

1
2 **Supplement to the ACTIV-6 COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of**
3 **Repurposed Medications Statistical Analysis Plan**
4
5

6 This analysis report describes the intended comparisons described in the ACTIV-6 Statistical Analysis
7 Plan. The study is a Bayesian platform trial with one primary outcome and multiple secondary outcomes.
8 The posterior distributions are presented to characterize the range of possible true effects based on the
9 observed data and are intended to be used to assess the strength of evidence on secondary outcomes.
10 The use of a posterior probability of 0.95 for decision making on the primary outcomes during interim
11 analyses implies the potential for dichotomous decision making on secondary endpoints. Should readers
12 apply a decision-making threshold to the secondary endpoints, they should consider that there are seven
13 pre-specified secondary outcomes that are not adjusted for multiplicity.
14

15 **Data Sharing Statement**

16 ACTIV-6 is a platform trial using shared placebos. On completion of the platform trial, when there is no
17 risk of unblinding across study arms, the data will be made publicly available by depositing it in an
18 approved data repository such as NHLBI's BioData Catalyst.
19